AZD-2563 AstraZeneca.

Abstract

AstraZeneca is developing AZD-2563, an oxazolidinone with a novel mechanism of action, for the potential treatment of gram-positive bacterial infections, including those caused by multidrug-resistant strains [349551], [399542]. As of December 2001, AZD-2563 had completed an escalating-dose phase I trial in the UK and was being developed in the US [433897]; at this time, AstraZeneca did not expect launch until after 2004 [431673]. In October 2001, Morgan Stanley estimated launch in 2004 with sales of US $20 million in that year, rising to US $46 million in following years [429700].

• Authors: Alan P Johnson
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 3 Issue 6 Pg. 848-52 (Jun 2002) ISSN: 1472-4472 [Print] England
• PMID: 12137402 (Publication Type: Journal Article, Review)

Chemical References

• Acetamides
• Anti-Bacterial Agents
• Oxazolidinones
• posizolid
• Linezolid

Topics

• Acetamides (pharmacology, therapeutic use)
• Animals
• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Disease Models, Animal
• Gram-Positive Bacteria (drug effects)
• Gram-Positive Bacterial Infections (drug therapy)
• Linezolid
• Microbial Sensitivity Tests
• Oxazolidinones (pharmacology, therapeutic use)
• Structure-Activity Relationship